Wegovy

A neurologist, an internist and an infection control expert join the show to discuss what made news in the health care this past month.

In a leadership shakeup, the diet company says CEO Sima Sistani would leave her role effective immediately. Tara Comonte, a board member and former Shake Shack exec, was named interim chief.

New research shows that the number of 12- to 25-year-olds who used the GLP-1 medications climbed from about 8,700 a month in 2020 to 60,000 a month in 2023.

But some health experts worry about traditional diet companies and gyms getting in the medication business and believe the drugs will cater to society’s need for quick fixes.

The European Medicines Agency regulatory committee joins the FDA in saying there's no known tie between the semaglutide obesity drugs and suicide.

Health officials say a preliminary review finds no connection between suicidal thoughts and a new class of diabetes and obesity drugs, but they cannot definitively rule out “a small risk may exist."

Weight-loss medications tamp down hunger — often dramatically — causing some people to lose the pleasure of communing over food at a festive family meal.

Many welcome what they say is greater control over what they eat. “I don’t care about the bread as much. I still eat what I enjoy,” says one Tampa area woman who lost more than 200 pounds taking Mounjaro.

Wegovy is a high-dose version of the diabetes treatment Ozempic. The international trial showed the weekly injections prevented heart attacks, strokes and heart-related deaths.

The drugs can slow digestion so much that it puts patients at increased risk for pulmonary aspiration, which can cause dangerous lung damage, infections and even death, says one anesthesiologist.